Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan

doi:10.4239/wjd.v6.i1.136

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11804)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

561

WORD

302

HTML

4746

Figures (1-3)

302

Tables (1-1)

547

Sum=6458

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

785

Download

1815

Sum=2600

Publishing Process of This Article

Item

Count

Browse

1194

Download

1552

Sum=2746

Feb 15, 2015 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Feb 15, 2015; 6(1): 136-144
Published online Feb 15, 2015. doi: 10.4239/wjd.v6.i1.136

Table 1 Sodium-glucose cotransporter 2 selectivity of sodium-glucose cotransporter 2 inhibitors

	Company	IC₅₀ for human SGLT1/SGLT2 (nmol/L)	SGLT2 selectivity (fold)
Phlorizin		210/34.6	6
Ipragliflozin	Astellas	1876/7.38	254
canagliflozin	Johnson and Johnson Mitsubishi Tanabe	684/4.4	155
Dapagliflozin	Bristol-Myers Squibb AstraZeneca	1391/1.12	1242
Empagliflozin	Boehringer Ingelheim	8300/3.1	2680
Tofogliflozin	Chugai	8444/2.9	2912
luseogliflozin	Taisho	3990/2.26	1770

SGLT2 selectivity was calculated by using the following formula: IC₅₀ value for SGLT1/IC₅₀ value for SGLT2. IC₅₀: Half maximal (50%) inhibitory concentration; SGLT: Sodium–glucose cotransporter.

Citation: Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015; 6(1): 136-144
URL: https://www.wjgnet.com/1948-9358/full/v6/i1/136.htm
DOI: https://dx.doi.org/10.4239/wjd.v6.i1.136